STAT3 and non-small cell lung carcinoma: These findings position PLK1 inhibitors as promising therapeutic agents, particularly when combined with targeted therapies that induce STAT3 activation, including EGFR/MEK/ERK inhibitors in EGFR-mutant NSCLC.